PG490-88, a derivative of triptolide, attenuates obliterative airway disease in a mouse heterotopic tracheal allograft model

Colm Leonard; Colm T. Leonard; Paola M. Soccal; Gerald J. Berry; Ramona L. Doyle; James Theodore; Steven R. Duncan; Glenn D. Rosen

PG490-88, a derivative of triptolide, attenuates obliterative airway disease in a mouse heterotopic tracheal allograft model

Colm Leonard, Colm T. Leonard, Paola M. Soccal, Gerald J. Berry, Ramona L. Doyle, James Theodore, Steven R. Duncan, Glenn D. Rosen

Research output: Contribution to journal › Article › peer-review

Abstract

The current treatment of obliterative bronchiolitis in lung transplant recipients is sub-optimal. Triptolide is a novel immunosuppressant that has a mechanism of action distinct from currently available immunosuppressants, including induction of T-cell apoptosis, blockade of fibroblast proliferation/maturation and inhibition of transforming growth factor-β (TGF-β) mRNA production. We hypothesized that triptolide may be helpful in blocking obliterative airway disease in lung transplant recipients. We investigated the effect of PG490-88, a water-soluble derivative of triptolide, in a mouse heterotopic tracheal allograft model of obliterative airway disease. We show that PG490-88 attenuates airway obliteration in this model and inhibits accumulation of inflammatory cells, and therefore may have preventive or therapeutic benefits for patients with obliterative airway disease (OAD) following lung transplantation.

Original language	English
Pages (from-to)	1314-1318
Number of pages	4
Journal	Journal of Heart and Lung Transplantation
Volume	21
Issue number	12
Publication status	Published - 1 Dec 2002

Keywords

Animal
etiology: Bronchiolitis Obliterans
Comparative Study
Disease Models, Animal
pharmacology: Diterpenes
Graft Rejection
Graft Survival
Immunohistochemistry
adverse effects: Lung Transplantation
Male
Mice
Mice, Inbred C57BL
Reference Values
Sensitivity and Specificity
pathology: Trachea
Transplantation, Heterotopic
Treatment Outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{a5959729aac14479b0a27d88acb950c3,

title = "PG490-88, a derivative of triptolide, attenuates obliterative airway disease in a mouse heterotopic tracheal allograft model",

abstract = "The current treatment of obliterative bronchiolitis in lung transplant recipients is sub-optimal. Triptolide is a novel immunosuppressant that has a mechanism of action distinct from currently available immunosuppressants, including induction of T-cell apoptosis, blockade of fibroblast proliferation/maturation and inhibition of transforming growth factor-β (TGF-β) mRNA production. We hypothesized that triptolide may be helpful in blocking obliterative airway disease in lung transplant recipients. We investigated the effect of PG490-88, a water-soluble derivative of triptolide, in a mouse heterotopic tracheal allograft model of obliterative airway disease. We show that PG490-88 attenuates airway obliteration in this model and inhibits accumulation of inflammatory cells, and therefore may have preventive or therapeutic benefits for patients with obliterative airway disease (OAD) following lung transplantation.",

keywords = "Animal, etiology: Bronchiolitis Obliterans, Comparative Study, Disease Models, Animal, pharmacology: Diterpenes, Graft Rejection, Graft Survival, Immunohistochemistry, adverse effects: Lung Transplantation, Male, Mice, Mice, Inbred C57BL, Reference Values, Sensitivity and Specificity, pathology: Trachea, Transplantation, Heterotopic, Treatment Outcome",

author = "Colm Leonard and Leonard, {Colm T.} and Soccal, {Paola M.} and Berry, {Gerald J.} and Doyle, {Ramona L.} and James Theodore and Duncan, {Steven R.} and Rosen, {Glenn D.}",

year = "2002",

month = dec,

day = "1",

language = "English",

volume = "21",

pages = "1314--1318",

journal = "Journal of Heart and Lung Transplantation",

issn = "1053-2498",

publisher = "Elsevier BV",

number = "12",

}

TY - JOUR

T1 - PG490-88, a derivative of triptolide, attenuates obliterative airway disease in a mouse heterotopic tracheal allograft model

AU - Leonard, Colm

AU - Leonard, Colm T.

AU - Soccal, Paola M.

AU - Berry, Gerald J.

AU - Doyle, Ramona L.

AU - Theodore, James

AU - Duncan, Steven R.

AU - Rosen, Glenn D.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - The current treatment of obliterative bronchiolitis in lung transplant recipients is sub-optimal. Triptolide is a novel immunosuppressant that has a mechanism of action distinct from currently available immunosuppressants, including induction of T-cell apoptosis, blockade of fibroblast proliferation/maturation and inhibition of transforming growth factor-β (TGF-β) mRNA production. We hypothesized that triptolide may be helpful in blocking obliterative airway disease in lung transplant recipients. We investigated the effect of PG490-88, a water-soluble derivative of triptolide, in a mouse heterotopic tracheal allograft model of obliterative airway disease. We show that PG490-88 attenuates airway obliteration in this model and inhibits accumulation of inflammatory cells, and therefore may have preventive or therapeutic benefits for patients with obliterative airway disease (OAD) following lung transplantation.

AB - The current treatment of obliterative bronchiolitis in lung transplant recipients is sub-optimal. Triptolide is a novel immunosuppressant that has a mechanism of action distinct from currently available immunosuppressants, including induction of T-cell apoptosis, blockade of fibroblast proliferation/maturation and inhibition of transforming growth factor-β (TGF-β) mRNA production. We hypothesized that triptolide may be helpful in blocking obliterative airway disease in lung transplant recipients. We investigated the effect of PG490-88, a water-soluble derivative of triptolide, in a mouse heterotopic tracheal allograft model of obliterative airway disease. We show that PG490-88 attenuates airway obliteration in this model and inhibits accumulation of inflammatory cells, and therefore may have preventive or therapeutic benefits for patients with obliterative airway disease (OAD) following lung transplantation.

KW - Animal

KW - etiology: Bronchiolitis Obliterans

KW - Comparative Study

KW - Disease Models, Animal

KW - pharmacology: Diterpenes

KW - Graft Rejection

KW - Graft Survival

KW - Immunohistochemistry

KW - adverse effects: Lung Transplantation

KW - Male

KW - Mice

KW - Mice, Inbred C57BL

KW - Reference Values

KW - Sensitivity and Specificity

KW - pathology: Trachea

KW - Transplantation, Heterotopic

KW - Treatment Outcome

M3 - Article

SN - 1053-2498

VL - 21

SP - 1314

EP - 1318

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

IS - 12

ER -

PG490-88, a derivative of triptolide, attenuates obliterative airway disease in a mouse heterotopic tracheal allograft model

Abstract

Keywords

UN SDGs

Fingerprint

Cite this